PDF]US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome  Kyowa Hakko Kirin News Releases

By JPN, Pharmaceutical

PDF]US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome  Kyowa Hakko Kirin News Releases

http://www.kyowa-kirin.com/news_releases/2017/pdf/e20170825_01.pdf

More from tokioX :

  1. Kyowa Kirin Announces FDA Approval of NOURIANZTM (istradefylline) for Use in Parkinson’s Disease
  2. 💊Kyowa Hakko Kirin, anti-Ccr4 humanized antibody acceptance application for European approval of Mogum Lysumab  20171027
  3. 💊Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson’s Disease with the US FDA
  4. 💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010
  5. 💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)
  6. FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer
  7. Kyowa Hakko Kirin and Kyowa Kirin International Announce Burosumab Data Presentations at ASBMR 2017 Annual Meeting